Thomas Joanne, Kim Lucas, Albini Thomas, Yeh Steven
Medical College of Georgia, Augusta, GA.
Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE.
Expert Rev Ophthalmol. 2022;17(3):165-173. doi: 10.1080/17469899.2022.2114456. Epub 2022 Aug 21.
Macular edema due to noninfectious uveitis is a sight-threatening complication that is routinely treated with corticosteroids. Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere) is an alternative treatment option for patients with non-infectious uveitis associated macular edema.
This review describes the recently FDA approved triamcinolone acetonide injectable suspension that can be injected into the suprachoroidal space. This physiological space is between the sclera and choroid. This allows for therapeutic targeting of the retina and choroid. This review highlights published clinical trials for this novel drug preparation.
Suprachoroidal administration of triamcinolone acetonide has shown improvement in vision and inflammation in studies with non-infectious uveitis associated macular edema. This unique delivery method suggests the potential to decrease side effects of anterior segment exposure such as glaucoma and cataract, but head-to-head trials are needed for further study of safety and efficacy. Additionally, there are promising prospective studies underway for utilization of the suprachoroidal space for other diseases including macular degeneration, diabetic macular edema, and ocular tumors.
非感染性葡萄膜炎所致黄斑水肿是一种威胁视力的并发症，通常采用皮质类固醇进行治疗。用于脉络膜上腔注射的曲安奈德注射用混悬液（Xipere）是治疗非感染性葡萄膜炎相关性黄斑水肿患者的一种替代治疗选择。
本综述介绍了最近获得美国食品药品监督管理局（FDA）批准的可注射到脉络膜上腔的曲安奈德注射用混悬液。这个生理空间位于巩膜和脉络膜之间。这使得能够对视网膜和脉络膜进行靶向治疗。本综述重点介绍了关于这种新型药物制剂已发表的临床试验。
在非感染性葡萄膜炎相关性黄斑水肿的研究中，脉络膜上腔注射曲安奈德已显示出视力和炎症有所改善。这种独特的给药方法表明有可能减少前段暴露的副作用，如青光眼和白内障，但需要进行直接对比试验以进一步研究其安全性和有效性。此外，正在进行有前景的前瞻性研究，探讨将脉络膜上腔用于其他疾病，包括黄斑变性、糖尿病性黄斑水肿和眼部肿瘤。
